Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Phase 3

Terminated

• Conditions: Choroidal Neovascularization; Angioid Streaks

• Registration Number: NCT00599820
• Lead Sponsor: Asociación para Evitar la Ceguera en México

Brief Summary

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Detailed Description

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Study Timeline

• Study Start: 2005-11
• Primary Completion: 2005-11
• Study Completion: 2006-05
• Study First Submitted: 2006-06-30
• Study First Submitted QC: 2008-01-23
• Study First Posted: 2008-01-24
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-31
• Last Update Posted: 2024-06-03

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Clinical diagnosis of Angioid Streaks
• Choroidal neovascularization associated
• Untreated patients or patients treated once with PDT

Exclusion Criteria

• Ocular surgery excepting uncomplicated phacoemulsification
• Glaucoma or any other ocular pathology

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Optical Coherence Tomography
BCVA
Fluoresceine Angiography

Trial Locations

Locations (1)

Asociación para Evitar la Ceguera en México (APEC); 🇲🇽 México city, Distrito Federal, Mexico